Identification of cyclophilin A as a potential prognostic factor for clear-cell renal cell carcinoma by comparative proteomic analysis

Cancer Biology and Therapy

Volumn 11, Issue 5, 2011, Pages 535-546

  Yang, Jin ^a   Li, Ang ^a   Yang, Yucong ^a   Li, Xu ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

2 DE; Clear cell renal cell carcinoma; Cyclophilin A; HK 2; MALDI TOF MS; Proteomics; RLC 310

Indexed keywords

CYCLOPHILIN A;

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOPHILIN A; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE EXPRESSION; HUMANS; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79952356198     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.5.14678     Document Type: Article

References (52)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108; PMID: 15761078; DOI: 10.3322/canjclin.55.2.74.
2. Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005; 14:243-50; PMID: 15668501.
3. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611-23; PMID: 11586189; DOI: 10.1016/S0022-5347(05)65640-6.
4. Uchida K, Miyao N, Masumori N, Takahashi A, Oda T, Yanase M, et al. Recurrence of renal cell carcinoma more than 5 years after nephrectomy. Int J Urol 2002; 9:19-23; PMID: 11972645; DOI: 10.1046/j.1442-2042.2002.00418.x
5. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 61:55-7; PMID: 10685660.
6. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21:1214-22; PMID: 12663707; DOI: 10.1200/JCO.2003.02.005.
7. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-24; PMID: 17215529.
8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-34; PMID: 17215530.
9. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-81; PMID: 17538086.
10. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116:4256-65; PMID: 20549832; DOI: 10.1002/cncr.25219.
11. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370:2103-11; PMID: 18156031; DOI: 10.1016/S0140-6736(07)61904-7.
12. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584-90; PMID: 19487381; DOI: 10.1200/JCO.2008.20.1293.
13. Simpson RJ, Dorow DS. Cancer proteomics: from signaling networks to tumor markers. Trends Biotechnol 2001; 19:40-8; PMID: 11780970; DOI: 10.1016/S0167-7799(01)01801-7.
14. Banks RE, Craven RA, Harnden P, Madaan S, Joyce A, Selby PJ. Key clinical issues in renal cancer: a challenge for proteomics. World J Urol 2007; 25:537-56; PMID: 17721703; DOI: 10.1007/s00345-007-0199-y.
15. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002; 1:683-95; PMID: 12209149; DOI: 10.1038/nrd891.
16. Arsanious A, Bjarnason GA, Yousef GM. From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol Cancer 2009; 8:20; PMID: 19291329; DOI: 10.1186/1476-4598-8-20.
17. Nogueira M, Kim HL. Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol 2008; 26:113-24; PMID: 18312928; DOI: 10.1016/j.urolonc.2007.03.028.
18. Wood SL, Rogers M, Cairns DA, Paul A, Thompson D, Vasudev NS, et al. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer 2010; 103:101-11; PMID: 20531413; DOI: 10.1038/sj.bjc.6605720.
19. Wang Y, Chen W, Li X. [Screening of differentially expressed genes in human renal cell carcinoma using suppression subtractive hybridization]. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28:89-93; PMID: 18227036; DOI: CNKI:SUN:DYJD.0.2008-01-028.
20. Bander NH, Finstad CL, Cordon-Cardo C, Ramsawak RD, Vaughan EJ, Whitmore WJ, et al. Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. Cancer Res 1989; 49:6774-80; PMID: 2684399.
21. Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, Torok-Storb B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 1994; 45:48-57; PMID: 8127021; DOI: 10.1038/ki.1994.6.
22. Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K, Tachibana M. Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer 2009; 101:287-94; PMID: 19513064; DOI: 10.1038/sj.bjc.6605128.
23. Zimmermann U, Woenckhaus C, Pietschmann S, Junker H, Maile S, Schultz K, et al. Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Arch 2004; 445:368-74; PMID: 15338305; DOI: 10.1007/s00428-004-1103-4.
24. Sun CY, Zang YC, San YX, Sun W, Zhang L. Proteomic analysis of clear cell renal cell carcinoma. Identification of potential tumor markers. Saudi Med J 2010; 31:525-32; PMID: 20464042.
25. Zacchia M, Vilasi A, Capasso A, Morelli F, De Vita F, Capasso G. Genomic and proteomic approaches to renal cell carcinoma. J Nephrol 2010; PMID: 20437403.
26. Bluemke K, Bilkenroth U, Meye A, Fuessel S, Lautenschlaeger C, Goebel S, et al. Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomarkers Prev 2009; 18:2190-4; PMID: 19661076; DOI: 10.1158/1055-9965.EPI-08-1178.
27. Kellner R, Lichtenfels R, Atkins D, Bukur J, Ackermann A, Beck J, et al. Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics 2002; 2:1743-51; PMID: 12469344; DOI: 10.1002/1615-9861(200212).
28. Lichtenfels R, Ackermann A, Kellner R, Seliger B. Mapping and expression pattern analysis of key components of the major histocompatibility complex class I antigen processing and presentation pathway in a representative human renal cell carcinoma cell line. Electrophoresis 2001; 22:1801-9; PMID: 11425235; DOI: 10.1002/1522-2683(200105).
29. Seliger B, Menig M, Lichtenfels R, Atkins D, Bukur J, Halder TM, et al. Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy. Proteomics 2003; 3:979-90; PMID: 12833523; DOI: 10.1002/pmic.200300404.
30. Peng H, Vijayakumar S, Schiene-Fischer C, Li H, Purkerson JM, Malesevic M, et al. Secreted cyclophilin A, a peptidylprolyl cis-trans isomerase, mediates matrix assembly of hensin, a protein implicated in epithelial differentiation. J Biol Chem 2009; 284:6465-75; PMID: 19112104; DOI: 10.1074/jbc.M808964200.
31. Kim SH, Lessner SM, Sakurai Y, Galis ZS. Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction. Am J Pathol 2004; 164:1567-74; PMID: 15111303.
32. Boulos S, Meloni BP, Arthur PG, Majda B, Bojarski C, Knuckey NW. Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury. Neurobiol Dis 2007; 25:54-64; PMID: 17011206; DOI: 10.1016/j.nbd.2006. 08.012.
33. + T cells via a proline-directed conformational switch in Itk. Immunity 2004; 21:189-201; PMID: 15308100; DOI: 10.1016/j.immuni.2004.07.005.
34. Arora K, Gwinn WM, Bower MA, Watson A, Okwumabua I, MacDonald HR, et al. Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol 2005; 175:517-22; PMID: 15972687.
35. Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EJ. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res 2003; 63:1652-6; PMID: 12670919.
36. Yang H, Chen J, Yang J, Qiao S, Zhao S, Yu L. Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal. Biochem Biophys Res Commun 2007; 361:763-7; PMID:17678621; DOI:10.1016/j.bbrc.2007.07. 085.
37. Shen J, Person MD, Zhu J, Abbruzzese JL, Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 2004; 64:9018-26; PMID: 15604267; DOI: 10.1158/0008-5427.CAN-04-3262.
38. Mikuriya K, Kuramitsu Y, Ryozawa S, Fujimoto M, Mori S, Oka M, et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol 2007; 30:849-55; PMID: 17332923; DOI:
39. Li Z, Zhao X, Bai S, Wang Z, Chen L, Wei Y, et al. Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics 2008; 7:1810-23; PMID: 18421009; DOI: 10.1074/mcp.M700544-MCP200.
40. Qi YJ, He QY, Ma YF, Du YW, Liu GC, Li YJ, et al. Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. J Cell Biochem 2008; 104:1625-35; PMID: 18320592; DOI: 10.1002/jcb.21727.
41. Vorum H, Ostergaard M, Hensechke P, Enghild JJ, Riazati M, Rice GE. Proteomic analysis of hyperoxia-induced responses in the human choriocarcinoma cell line JEG-3. Proteomics 2004; 4:861-7; PMID: 14997506; DOI: 10.1002/pmic.200300639.
42. Zheng J, Koblinski JE, Dutson LV, Feeney YB, Clevenger CV. Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. Cancer Res 2008; 68:7769-78; PMID: 18829531; DOI: 10.1158/0008-5472.CAN-08-0639.
43. Lim SO, Park SJ, Kim W, Park SG, Kim HJ, Kim YI, et al. Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun 2002; 291:1031-7; PMID: 11866469; DOI: 10.1006/bbrc.2002.6547.
44. Wong CS, Wong VW, Chan CM, Ma BB, Hui EP, Wong MC, et al. Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol Rep 2008; 20:89-98; PMID: 18575723.
45. Al-Ghoul M, Bruck TB, Lauer-Fields JL, Asirvatham VS, Zapata C, Kerr RG, et al. Comparative proteomic analysis of matched primary and metastatic melanoma cell lines. J Proteome Res 2008; 7:4107-18; PMID: 18698805; DOI: 10.1021/pr800174k.
46. Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E, et al. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer 2004; 46:313-23; PMID: 15541816; DOI: 10.1016/j.lungcan.2004.05.013.
47. Jin ZG, Lungu AO, Xie L, Wang M, Wong C, Berk BC. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol 2004; 24:1186-91; PMID: 15130913; DOI: 10.1161/01.ATV.0000130664. 51010.28.
48. Jin ZG, Melaragno MG, Liao DF, Yan C, Haendeler J, Suh YA, et al. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res 2000; 87:789-96; PMID: 11055983.
49. Howard BA, Furumai R, Campa MJ, Rabbani ZN, Vujaskovic Z, Wang XF, et al. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res 2005; 65:8853-60; PMID: 16204056; DOI: 10.1158/0008-5472.CAN-05-1219.
50. Zacchia M, Vilasi A, Capasso A, Morelli F, De Vita F, Capasso G. Genomic and proteomic approaches to renal cell carcinoma. J Nephrol 2010; PMID: 20437403.
51. Choi KJ, Piao YJ, Lim MJ, Kim JH, Ha J, Choe W, et al. Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res 2007; 67:3654-62; PMID: 17440077; DOI: 10.1158/0008-5472.CAN-06-1759.
52. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23:832-41; PMID: 15681528; DOI: 10.1200/JCO.2005.05.179.